Avastin FDA Approval History
Last updated by Judith Stewart, BPharm on May 5, 2021.
FDA Approved: Yes (First approved February 26, 2004)
Brand name: Avastin
Generic name: bevacizumab
Dosage form: Injection
Company: Genentech, Inc.
Treatment for: Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Hepatocellular Carcinoma
Avastin (bevacizumab) is a recombinant humanized monoclonal IgG1 antibody for the treatment of colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, and hepatocellular carcinoma.
Development timeline for Avastin
| Date | Article |
|---|
| Oct 13, 2021 | Approval FDA Approves Merck’s Keytruda (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1) |
| May 29, 2020 | Approval FDA Approves Genentech’s Tecentriq in Combination With Avastin for People With Hepatocellular Carcinoma |
| Dec 6, 2018 | Approval FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer |
| Jun 13, 2018 | Approval FDA Approves Genentech’s Avastin (bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery |
| Dec 5, 2017 | Approval FDA Grants Genentech’s Avastin Full Approval for Most Aggressive Form of Brain Cancer |
| Dec 6, 2016 | Approval FDA Approves Avastin (bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer |
| Nov 14, 2014 | Approval FDA Approves Avastin (bevacizumab) Plus Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer |
| Aug 14, 2014 | Approval FDA Approves Avastin for Metastatic Cervical Cancer |
| Nov 18, 2011 | Approval FDA Revokes Breast Cancer Indication for Avastin (bevacizumab) |
| Aug 3, 2009 | Approval FDA Approves Avastin for the Most Common Type of Kidney Cancer |
| May 6, 2009 | Approval FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy |
| Feb 25, 2008 | Approval FDA Grants Accelerated Approval of Avastin in Combination With
Paclitaxel Chemotherapy for First-Line Treatment of Advanced
HER2-Negative Breast Cancer |
| Oct 11, 2006 | Approval FDA Approves Avastin in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer |
| Apr 12, 2006 | Avastin Filed in US for Treatment of Most Common Form of Lung Cancer |
| Feb 26, 2004 | Approval Avastin Approved for treatment for Metastatic Colorectal Cancer |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medical Disclaimer
